Do Not Let HCPs Delay Your Biologics Route To Market
Source: Cytiva

The stakes are high in biologics development, especially in host cell protein (HCP) analysis. Get it wrong and it could delay your development cycle. See how optimizing your HCP assays can smooth your route to market.
In this article, review Chinese hamster ovary (CHO) cells, the challenge of analyzing HCPs, analyzing HCPs in biosimilars, and how to determine which HCP ELISA coverage assay to use.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Cytiva
This website uses cookies to ensure you get the best experience on our website. Learn more